Suzhou Basecare Medical Corporation Limited (Basecare), a company in the free trade zone in SIP, is emerging as a global player in assisted reproductive technology through its dual-engine strategy of “independent R&D and global expansion”.
Founded in 2010, the company has been engaged in developing high-quality solutions for reproduction and healthcare. In recent years, it has been enhancing independent R&D to strengthen its competitiveness in global market.
A milestone came in 2020, when Basecare developed China’s first NMPA-approved PGT-A kit for third-generation in-vitro fertilization (IVF), filling a critical gap in clinical reagents. The product has gained rapid market acceptance and is now exported to Thailand, Singapore, Australia and other countries and regions.
The company’s self-developed ultra-low temperature storage device, capable of storing 30,000 samples and supporting remote monitoring and automatic operation, has been deployed in Hong Kong, with plans to expand into Europe and Asia-Pacific in the future.
Another breakthrough product, an AI-powered sperm quality analyzer, is already in clinical use in Australia and Europe.
In order to expand its global footprint, the company acquired Genea Biomedx, world-leading fertility group Genea’s high-end medical devices arm in Singapore. By manufacturing Genea Biomedx’s products, Basecare can enrich its product lineup, and the former’s global marketing network and experience can help it expand the global market share of its independently developed products.
With its Suzhou headquarters as the core, Basecare has established branches in Beijing, Shanghai, Guangzhou and Hong Kong domestically, and international offices in Singapore, the United Kingdom, Spain, Australia and the United States. Its products, backed by over 70 global medical device certifications, are used in more than 900 reproductive centers across 60 countries.
November 5, 2025
